Mitoquinone alleviates osteoarthritis progress by activating the NRF2-Parkin axis

Liangcai Hou,Genchun Wang,Xiong Zhang,Fan Lu,Jingting Xu,Zhou Guo,Jiamin Lin,Zehang Zheng,Haigang Liu,Yanjun Hou,Kai Sun,Fengjing Guo
DOI: https://doi.org/10.1016/j.isci.2023.107647
IF: 5.8
2023-08-01
iScience
Abstract:Osteoarthritis (OA) is a prevalent degenerative disease of the elderly. The NRF2 antioxidant system plays a critical role in maintaining redox balance. Mitoquinone (MitoQ) is a mitochondria-targeted antioxidant. This research aimed to determine whether MitoQ alleviated OA and the role of the NRF2/Parkin axis in MitoQ-mediated protective effects. In interleukin (IL)-1β-induced OA chondrocytes, MitoQ activated the NRF2 pathway, reducing extracellular matrix (ECM) degradation and inflammation. MitoQ also increased glutathione peroxidase 4 (GPX4) expression, leading to decreased levels of reactive oxygen species (ROS) and lipid ROS. Silencing NRF2 weakened MitoQ's protective effects, while knockdown of Parkin upregulated the NRF2 pathway, inhibiting OA progression. Intra-articular injection of MitoQ mitigated cartilage destruction in destabilized medial meniscus (DMM)-induced OA mice. Our study demonstrates that MitoQ maintains cartilage homeostasis <i>in vivo</i> and <i>in vitro</i> through the NRF2/Parkin axis. We supplemented the negative feedback regulation mechanism between NRF2 and Parkin. These findings highlight the therapeutic potential of MitoQ for OA treatment.
multidisciplinary sciences
What problem does this paper attempt to address?